Safety of Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma, A Phase I/II Study, Short Title: VBDD.

Trial Profile

Safety of Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma, A Phase I/II Study, Short Title: VBDD.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Vorinostat (Primary) ; Bortezomib; Dexamethasone; Doxorubicin
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms VBDD
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed as per European Clinical Trials Database record.
    • 27 Jun 2014 Planned End Date changed from 1 Sep 2014 to 1 Mar 2017 reported by ClinicalTrials.gov.
    • 18 Jan 2012 German Clinical Trials Register reports actual initiation date as 20 Sep 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top